Literature DB >> 18793712

Norman Cousins Lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface.

Andrew H Miller1.   

Abstract

Work in our laboratory has focused on the mechanisms by which cytokines can influence the brain and behavior in humans and non-human primates. Using administration of interferon (IFN)-alpha as a tool to unravel these mechanisms, we have expanded upon findings from the basic science literature implicating cytokine-induced changes in monoamine metabolism as a primary pathway to depression. More specifically, a role for serotonin metabolism has been supported by the clinical efficacy of serotonin reuptake inhibitors in blocking the development of IFN-alpha-induced depression, and the capacity of IFN-alpha to activate metabolic enzymes (indolamine 2,3 dioxygenase) and cytokine signaling pathways (p38 mitogen activated protein kinase) that can influence the synthesis and reuptake of serotonin. Our data also support a role for dopamine depletion as reflected by IFN-alpha-induced changes in behavior (psychomotor slowing and fatigue) and regional brain activity, which implicate the involvement of the basal ganglia, as well as the association of IFN-alpha-induced depressive-like behavior in rhesus monkeys with decreased cerebrospinal fluid concentrations of the dopamine metabolite, homovanillic acid. Neuroimaging data in IFN-alpha-treated patients also suggest that activation of neural circuits (dorsal anterior cingulate cortex) associated with anxiety and alarm may contribute to cytokine-induced behavioral changes. Taken together, these effects of cytokines on the brain and behavior appear to subserve competing evolutionary survival priorities that promote reduced activity to allow healing, and hypervigilance to protect against future attack. Depending on the relative balance between these behavioral accoutrements of an activated innate immune response, clinical presentations may be distinct and warrant individualized therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18793712      PMCID: PMC2745948          DOI: 10.1016/j.bbi.2008.08.006

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  125 in total

1.  Oscillations in the basal ganglia.

Authors:  T Wichmann; M R DeLong
Journal:  Nature       Date:  1999-08-12       Impact factor: 49.962

2.  Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state.

Authors:  L Capuron; A Ravaud
Journal:  N Engl J Med       Date:  1999-04-29       Impact factor: 91.245

3.  A case of akathisia during interferon-alpha therapy for chronic hepatitis type C.

Authors:  N Horikawa; T Yamazaki; M Sagawa; T Nagata
Journal:  Gen Hosp Psychiatry       Date:  1999 Mar-Apr       Impact factor: 3.238

4.  Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain?

Authors:  H-Q Wu; A Rassoulpour; R Schwarcz
Journal:  J Neural Transm (Vienna)       Date:  2006-08-24       Impact factor: 3.575

5.  Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.

Authors:  Charles L Raison; Andrey S Borisov; Sherry D Broadwell; Lucile Capuron; Bobbi J Woolwine; Ira M Jacobson; Charles B Nemeroff; Andrew H Miller
Journal:  J Clin Psychiatry       Date:  2005-01       Impact factor: 4.384

6.  mu- but not delta- and kappa-opioid receptor mediates the nucleus submedius interferon-alpha-evoked antinociception in the rat.

Authors:  Jun-Yang Wang; Xiao-Yan Zeng; Gui-Xiang Fan; Yu-Kang Yuan; Jing-Shi Tang
Journal:  Neurosci Lett       Date:  2006-01-09       Impact factor: 3.046

7.  Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy.

Authors:  Lucile Capuron; Giuseppe Pagnoni; Marina F Demetrashvili; David H Lawson; Fiona B Fornwalt; Bobbi Woolwine; Gregory S Berns; Charles B Nemeroff; Andrew H Miller
Journal:  Neuropsychopharmacology       Date:  2007-02-28       Impact factor: 7.853

8.  Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy.

Authors:  Lucile Capuron; Charles L Raison; Dominique L Musselman; David H Lawson; Charles B Nemeroff; Andrew H Miller
Journal:  Am J Psychiatry       Date:  2003-07       Impact factor: 18.112

9.  Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood-brain barrier.

Authors:  Tomitsune Kitagami; Kiyofumi Yamada; Hideki Miura; Ryo Hashimoto; Toshitaka Nabeshima; Tatsurou Ohta
Journal:  Brain Res       Date:  2003-07-18       Impact factor: 3.252

10.  Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene.

Authors:  Avshalom Caspi; Karen Sugden; Terrie E Moffitt; Alan Taylor; Ian W Craig; HonaLee Harrington; Joseph McClay; Jonathan Mill; Judy Martin; Antony Braithwaite; Richie Poulton
Journal:  Science       Date:  2003-07-18       Impact factor: 47.728

View more
  92 in total

1.  Ascending caudal medullary catecholamine pathways drive sickness-induced deficits in exploratory behavior: brain substrates for fatigue?

Authors:  Ronald P A Gaykema; Lisa E Goehler
Journal:  Brain Behav Immun       Date:  2010-11-12       Impact factor: 7.217

Review 2.  Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications.

Authors:  Julienne E Bower; Donald M Lamkin
Journal:  Brain Behav Immun       Date:  2012-07-06       Impact factor: 7.217

3.  Rapid Regulation of Depression-Associated Genes in a New Mouse Model Mimicking Interferon-α-Related Depression in Hepatitis C Virus Infection.

Authors:  Carolina Hoyo-Becerra; Zijian Liu; Jinghong Yao; Britta Kaltwasser; Guido Gerken; Dirk M Hermann; Joerg F Schlaak
Journal:  Mol Neurobiol       Date:  2014-08-27       Impact factor: 5.590

Review 4.  Depression in people with coronary heart disease: prognostic significance and mechanisms.

Authors:  Chris Dickens
Journal:  Curr Cardiol Rep       Date:  2015-10       Impact factor: 2.931

5.  Association study between functional polymorphisms in the TNF-alpha gene and obsessive-compulsive disorder.

Authors:  Carolina Cappi; Renan Kawano Muniz; Aline Santos Sampaio; Quirino Cordeiro; Helena Brentani; Selma A Palácios; Andrea H Marques; Homero Vallada; Eurípedes Constantino Miguel; Luiza Guilherme; Ana Gabriela Hounie
Journal:  Arq Neuropsiquiatr       Date:  2012-02       Impact factor: 1.420

6.  The emergence of obsessive compulsive and compulsive buying symptomatology after acute stress and short-term use of ribavirin: case reports.

Authors:  Görkem Karakaş Uğurlu; Mustafa Uğurlu; Ali Cayköylü
Journal:  Ther Adv Psychopharmacol       Date:  2013-08

Review 7.  Inflammation-associated depression: from serotonin to kynurenine.

Authors:  Robert Dantzer; Jason C O'Connor; Marcus A Lawson; Keith W Kelley
Journal:  Psychoneuroendocrinology       Date:  2010-10-30       Impact factor: 4.905

8.  Depressive symptoms among cancer patients in a Philippine tertiary hospital: prevalence, factors, and influence on health-related quality of life.

Authors:  Jocelyn C Que; Teresa T Sy Ortin; Karen O Anderson; Consuelo B Gonzalez-Suarez; Thomas W Feeley; Cielito C Reyes-Gibby
Journal:  J Palliat Med       Date:  2013-09-18       Impact factor: 2.947

9.  Recommendations for high-priority research on cancer-related fatigue in children and adults.

Authors:  Andrea M Barsevick; Michael R Irwin; Pamela Hinds; Andrew Miller; Ann Berger; Paul Jacobsen; Sonia Ancoli-Israel; Bryce B Reeve; Karen Mustian; Ann O'Mara; Jin-Shei Lai; Michael Fisch; David Cella
Journal:  J Natl Cancer Inst       Date:  2013-09-18       Impact factor: 13.506

10.  Caregiver-reported neuropsychiatric symptoms in patients undergoing treatment for head and neck cancer: a pilot study.

Authors:  Stewart M Bond; Deborah K Hawkins; Barbara A Murphy
Journal:  Cancer Nurs       Date:  2014 May-Jun       Impact factor: 2.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.